Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.2552W HIGH $17.31
Volume
940.00
Value Traded
498.99 K
Short % Float
2.53%
Days to Cover
7.3
+0.17%Week
+0.17%1 Month
-14.36%3 Month
-14.96%6 Month
-84.32%5 Year
-99.88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
259.18 M
EPS (TTM)
-0.91
P/E Ratio
-
Ent. Value
-67.58 M
Total Shares
21.12 M
Float Shares
21.08 M
Insiders
0.02%
Institutions
20.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
AMRN Catalyst Timeline
Dated clinical, regulatory and corporate events for Amarin Corporation plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amarin Corporation plc
854Total events
9Upcoming
176Tier-1 (high impact)
2010 to 2039Coverage
Upcoming catalysts 2
Event history 50
▲Quarterly UpdateCorporate
Amarin reports Q3 2026 financial results with first profitable quarter in over two years
▲Secondary Endpoint DataVASCEPAApprovedClinical Data
EMT2 key secondary overall survival endpoint met with ~32% reduction in risk of death
colorectal cancer liver metastases (CRCLM)source ↗
▼Topline ReadoutVASCEPAApprovedClinical Data
EMT2 Phase 3 topline results presented: PFS primary endpoint not met, OS improved
colorectal cancer liver metastases (CRCLM)source ↗
▼Primary Endpoint MissedVASCEPAApprovedClinical Data
EMT2 did not meet primary endpoint of progression-free survival
colorectal cancer liver metastases (CRCLM)source ↗
●Late-BreakerVASCEPAApprovedPresentation
EMT2 results presented as late breaker at ESMO 2026 Congress
colorectal cancer liver metastases (CRCLM)source ↗
▲Late-BreakerVASCEPAApprovedPresentation
EMT2 Phase 3 investigator-initiated trial results presented as late breaker at ESMO 2026 Congress
colorectal cancer liver metastases (CRCLM)source ↗
▲Product LaunchVASCEPAApprovedPost-Market
VAZKEPA launched into private pay (non-reimbursed) market in Poland
cardiovascular risk reductionsource ↗
◆Oral PresentationVASCEPAApprovedPresentation
Oral presentation of REDUCE-IT Lp(a) Variability at ESC 2026
cardiovascular diseasesource ↗
◆Poster PresentationVASCEPAApprovedPresentation
Poster presentation on adherence and legacy effects of EPA in REDUCE-IT Legacy
hypertriglyceridemia and high CV risksource ↗
▲Oral PresentationVASCEPAApprovedPresentation
REDUCE-IT Legacy Analysis Presented at ESC Congress 2026
cardiovascularsource ↗
●Oral PresentationVASCEPAApprovedPresentation
Multiple Amarin-supported presentations at ESC Congress 2026
cardiovascular diseasesource ↗
▲FDA ApprovalFDA Decision
FDA approval of injectable APOC3 therapies for sHTG
severe hypertriglyceridemiasource ↗
▲Quarterly UpdateVASCEPAApprovedCorporate
VASCEPA branded prescriptions rose by 14% from Q2 2025
▲Restructuring LayoffsCorporate
Restructuring plan on track; full OPEX savings expected by mid-2026
▲Other Regulator MilestoneVASCEPAApprovedEx-US Regulatory
VAZKEPA commercially available in 11 European countries as of June 30, 2026
cardiovascular diseasesource ↗
▲Other Regulator MilestoneVASCEPAApprovedEx-US Regulatory
VASCEPA/VAZKEPA commercially available in 22 countries globally as of June 30, 2026
cardiovascular diseasesource ↗
▲Product LaunchVASCEPAApprovedPost-Market
VAZKEPA commercially available in 11 European countries as of June 30, 2026
▲Product LaunchVASCEPAApprovedPost-Market
VASCEPA/VAZKEPA commercially available in 22 countries globally as of June 30, 2026
▲Quarterly UpdateCorporate
U.S. IPE market share increased to 48% in Q2 2026 from 43% in Q2 2025
●Oral PresentationPresentation
Post hoc analysis of REDUCE-IT presented at EAS Congress 2026
cardiovascular diseasesource ↗
▲Oral PresentationVASCEPAApprovedPresentation
Secondary analysis of REDUCE-IT presented at ACC 2026
cardiovascular risk reductionsource ↗
●Poster PresentationVASCEPAApprovedPresentation
Poster on EPA inhibition of Lp(a) oxidation presented at ACC 2026
cardiovascular diseasesource ↗
▼Restructuring LayoffsCorporate
Recognized $3.3M restructuring charge in Q1 2026; cumulative $39.6M through Q1 2026
◆Oral PresentationVASCEPAApprovedPresentation
Efficacy of Icosapent Ethyl Among Patients at Extreme Cardiovascular Risk: A Secondary Analysis of REDUCE-IT
cardiovascular diseasesource ↗
◆Poster PresentationVASCEPAApprovedPresentation
Rates of Lipoprotein(a) Oxidation Increase at Elevated Levels in Non-linear Fashion and Inhibited by Eicosapentaenoic Acid (EPA)
cardiovascular diseasesource ↗
▲Oral PresentationVASCEPAApprovedPresentation
2026 ACC/AHA/Multisociety Dyslipidemia Guideline Update recommending icosapent ethyl
cardiovascular risk reduction in patients with hypertriglyceridemiasource ↗
▲Oral PresentationPresentation
2026 ACC/AHA/Multisociety Dyslipidemia Guideline reaffirmed role of VASCEPA
dyslipidemiasource ↗
▲PublicationVASCEPAApprovedPresentation
Post hoc analysis of REDUCE-IT published in European Journal of Preventive Cardiology
cardiovascular diseasesource ↗
●Oral PresentationPresentation
Business development and investor meetings at J.P. Morgan Healthcare Conference
▼Restructuring LayoffsCorporate
Remaining restructuring charges expected to be realized in early 2026
▲Quarterly UpdateCorporate
FY 2026 outlook: continued growth in international markets, maintenance of U.S. market share, improved OPEX, positive cash flow
▲Other Regulator MilestoneVASCEPAApprovedEx-US Regulatory
2026 ESC/ERA Guideline recognizes REDUCE-IT RENAL evidence
cardiovascular disease and chronic kidney diseasesource ↗
◆Timing GuidancePresentation
Commercial transition to Recordati expected to be largely completed by end of 2025
▲Oral PresentationVASCEPAApprovedPresentation
New REDUCE-IT Aspirin Analysis Presented at AHA Scientific Sessions 2025
cardiovascular risk reductionsource ↗
◆Oral PresentationVASCEPAApprovedPresentation
New analyses from REDUCE-IT evaluating clinical benefit of IPE on CV outcomes with or without baseline aspirin use
cardiovascular risk reductionsource ↗
◆Poster PresentationVASCEPAApprovedPresentation
Mechanistic studies on anti-oxidant effects of EPA on Lp(a) and anti-inflammatory/endothelial-protective properties
cardiovascular risk reductionsource ↗
▼Restructuring LayoffsCorporate
Global Restructuring Plan implementation charges recognized in Q3 2025
▲Partnership / LicenseVASCEPAApprovedCorporate
Transition to fully partnered commercialization model across all international markets completed
cardiovascular diseasesource ↗
▲Label ExpansionFDA Decision
FDA revises labeling for fenofibrate drugs to state lack of cardiovascular benefit
cardiovascular risk reductionsource ↗
◆Oral PresentationPresentation
Oral presentation of REDUCE-IT and EPA mechanistic data at CCC 2025
cardiovascular diseasesource ↗
◆Poster PresentationPresentation
Poster presentation of REDUCE-IT and EPA mechanistic data at CCC 2025
cardiovascular diseasesource ↗
▲Partnership / LicenseVASCEPAApprovedCorporate
Recordati commenced commercial efforts in 10 countries, including Italy launch in Q4 2025
cardiovascular risk reductionsource ↗
Past FDA Catalysts and PDUFA Decisions
How AMRN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2019-12-13 | Vascepa (icosapent ethyl) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 67%
Micro Cap(rank 452 of 674)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2026; product lines: last four quarters to Sep 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| VASCEPA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Icosapent Ethyl Small moleculeNot countedNCT04460651 | COVID19 | Phase 3 | COMPLETED | 4,093 | Aug 30, 2021 | ||||||
| AMR101-day Small moleculeMarketedNCT01047501 | Hypertriglyceridemia | Approved | COMPLETED | 931 | Feb 1, 2011 | ||||||
| AMR101-day Small moleculeMarketedNCT01492361 | Cardiovascular Diseases | Approved | COMPLETED | 8,179 | May 1, 2018 | ||||||
| Icosapent Ethyl Small moleculeNot countedNCT04412018 | COVID-19 | Phase 2 | COMPLETED | 100 | Dec 12, 2020 | ||||||
| Rotigotine Delivery System Small moleculeCompletedNCT07769359 | Undisclosed | Phase 1 | COMPLETED | 35 | Feb 26, 2026 | ||||||
| Icosapent Ethyl Small moleculeNot countedNCT03885661 | Lipid Disorder | Phase 1 | COMPLETED | 20 | Jun 1, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every AMRN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VAZKEPA/VASCEPA | colorectal cancer liver metastases | Phase 3 | 2026-10-25 | median PFS: 13.5 months with IPE versus 12.9 months with placebo; 5 year OS estimate: 62.0% with IPE versus 45.1% with placebo; risk of death reduction: approximately 32%Read More | Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fishman Peter L.Officer (SVP, CFO) | Option | 313 7,774 held | $0.00 | 08/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AMRN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 0.5 % (25 %) | 8.50 M | 532.98 K | 12.83% ( 60.60 K) |
Ownership Trends
AMRN Short Interest
Shares sold short, counted twice a month.
2.53%
Short % of Float
of tradable shares sold short
532.7K
Shares Sold Short
+0.8% vs prior count
7.3 High
Days to Cover
trading days of normal volume to buy every short share back
73.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AMRN ranks across every disease it competes in
Competitive Position is a premium feature
See how AMRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAMRN News
AMRN▲ +6.7%on this news
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
Amarin Corporation reported its third quarter financial results for 2026, achieving positive net income and strong momentum in its international business strategy. The company noted a 68% increase in demand for VAZKEPA in Europe and maintained a 47% market share in the U.S. IPE market. Financial highlights included a significant reduction in operating expenses and a cash balance exceeding $323 million.
Read more →AMRNAmarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Amarin Corporation reported findings from the Phase 3 EMT2 trial, which evaluated VAZKEPA/VASCEPA in patients undergoing liver resection for colorectal cancer liver metastases. While the primary endpoint of progression-free survival was not achieved, the trial demonstrated a significant improvement in overall survival, with a 32% reduction in the risk of death at five years. The findings suggest potential benefits of IPE in this patient population.
Read more →AMRNAmarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
Amarin Corporation announced it will report its third quarter 2026 financial results on October 28, 2026. A press release will be issued before the market opens, followed by a conference call at 8:00 a.m. ET. The call will provide insights into the company's performance and future outlook.
Read more →AMRNAmarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Amarin Corporation presented new findings at the ESC Congress 2026, highlighting the significance of icosapent ethyl in cardiovascular disease management. Research focused on treatment adherence, long-term outcomes, and the biological mechanisms of eicosapentaenoic acid (EPA). The findings support the efficacy of icosapent ethyl in reducing cardiovascular risk, particularly in high-risk patients.
Read more →AMRNNew REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Amarin Corporation presented new data from the REDUCE-IT trial at the ESC Congress 2026. The analysis showed a 30% relative risk reduction in major adverse cardiovascular events for highly adherent patients. Secondary prevention patients who stopped treatment after 2.3 years maintained a hazard ratio of 0.73 for subsequent years. These results suggest persistent cardiovascular benefits following the cessation of icosapent ethyl therapy.
Read more →AMRNNew Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
Amarin Corporation announced that it will present new analyses from the REDUCE-IT study at the European Society of Cardiology Congress 2026 in Munich. The presentations will cover various aspects of cardiovascular risk factors and biomarkers associated with icosapent ethyl. Key topics include treatment adherence and the effects of EPA on coagulation biomarkers. These findings aim to enhance understanding of cardiovascular disease management.
Read more →AMRNAmarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Amarin Corporation reported its Q2 2026 financial results, showcasing a 59% increase in international sales of VASCEPA/VAZKEPA compared to the previous year. The company successfully reduced operating expenses by 38%, contributing to positive cash flow for the third consecutive quarter. Despite a decline in total net revenue, Amarin maintains a strong market presence in the U.S. and anticipates continued growth in international markets.
Read more →AMRNAmarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
Amarin Corporation plc has announced it will report its second quarter 2026 financial results on July 29, 2026. A press release will be issued before the market opens, followed by a conference call at 8:00 a.m. ET. The call will be accessible via telephone and online, with a replay available after the event.
Read more →AMRNAmarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Amarin Corporation reaffirms the role of VASCEPA in managing severe hypertriglyceridemia amidst the recent FDA approval of injectable APOC3 therapies. CEO Aaron Berg highlights VASCEPA's proven efficacy, lower cost, and broad access compared to newer, more expensive options. The company emphasizes the importance of prioritizing established therapies like VASCEPA for patients at risk of cardiovascular events.
Read more →AMRNNew REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
Amarin Corporation presented new findings from a post hoc analysis of the REDUCE-IT trial at the EAS Congress 2026. The analysis indicates that risk-weighted apolipoprotein B (RW-apoB) can more effectively identify residual cardiovascular risk in statin-treated patients with elevated triglycerides compared to traditional lipid markers. This suggests RW-apoB's potential for improving risk stratification in clinical practice.
Read more →AMRNAmarin Reports 2026 First Quarter Financial Results
Amarin Corporation reported a 7% increase in total revenue for Q1 2026, driven by higher international sales and positive cash flow for the second consecutive quarter. The company noted strong demand for its product VAZKEPA in Europe, supported by new industry guidelines endorsing Icosapent Ethyl for cardiovascular risk management. Despite a slight decline in European revenue, the overall performance reflects a positive trend under its new business model.
Read more →AMRNAmarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
Amarin Corporation announced it will report its first quarter 2026 financial results on April 29, 2026. A press release will precede a conference call with senior management at 8:00 a.m. ET. The call will be accessible via telephone and online, with a replay available for later access.
Read more →AMRNAmerican College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction
Amarin Corporation highlighted key findings from the ACC Scientific Sessions 2026, emphasizing the role of icosapent ethyl (IPE) in managing elevated triglycerides and cardiovascular risk. The new ACC/AHA guidelines stress the need for complementary therapies beyond statins to address residual cardiovascular risk. Presentations at the event reinforced the efficacy of IPE in high-risk populations, while also noting limitations of current therapies.
Read more →AMRNAmarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
Amarin Corporation has praised the updated 2026 ACC/AHA/Multisociety Dyslipidemia Guidelines, which recommend the use of icosapent ethyl in managing cardiovascular risk for patients with elevated triglycerides. These guidelines encourage a comprehensive approach to cardiovascular risk management, moving beyond just LDL-C levels. The inclusion of icosapent ethyl as a recommended adjunct therapy highlights its proven effectiveness in reducing cardiovascular events in high-risk patients. Amarin views this update as a significant advancement in patient care and a validation of their commitment to addressing cardiovascular health.
Read more →AMRNNew REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
Amarin Corporation announced that new data from the REDUCE-IT study will be presented at the American College of Cardiology's Annual Scientific Session & Expo. The presentations will include a secondary analysis of the efficacy of icosapent ethyl in patients at extreme cardiovascular risk and mechanistic data on lipoprotein(a) oxidation. This highlights Amarin's commitment to addressing cardiovascular disease.
Read more →AMRNEffects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
A recent post hoc analysis of the REDUCE-IT study published in the European Journal of Preventive Cardiology indicates that icosapent ethyl (IPE) significantly reduces total hospitalizations and days lost due to hospitalization and death among patients with cardiovascular disease or diabetes. The analysis involved 8,179 participants over five years, demonstrating the treatment's impact on patient-centered outcomes. Experts emphasize the importance of these findings for improving patients' quality of life.
Read more →AMRN▼ -9.5%on this newsshared move
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
Amarin Corporation reported its fourth quarter and full year 2025 financial results, highlighting a positive shift in operational efficiency and market positioning. The company maintained its U.S. market leadership for VASCEPA and established a long-term partnership for VAZKEPA in Europe. Despite a 21% decrease in total net revenue, significant cost savings and a return to positive cash flow were achieved.
Read more →AMRNThis American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
Amarin urges the medical community to prioritize existing cardiovascular therapies during American Heart Month. The company highlights that 130.6 million U.S. adults lived with cardiovascular disease in 2023. This condition remains the leading cause of death in the United States. Amarin emphasizes the need to treat patients who are currently underutilizing proven, available treatments.
Read more →AMRNAmarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
Amarin Corporation plc has announced it will report its fourth quarter and full year 2025 financial results on February 25, 2026. The company will issue a press release in the pre-market hours, followed by a conference call at 8:00 a.m. ET. Investors can participate via telephone or online, with replay options available afterward.
Read more →AMRNAmarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
Amarin Corporation highlights advancements in therapies for patients with elevated triglycerides, particularly emphasizing the role of its VASCEPA/VAZKEPA products. These therapies are expected to enhance patient access and treatment strategies, especially through payor-driven step therapy programs. VASCEPA has shown significant efficacy in reducing cardiovascular events and is approved in multiple countries.
Read more →About Amarin Corporation plc
HeadquartersSPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Founded1989
BIOPHARMAWATCH ELITE PLUS
Trade the next AMRN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime